Danaher Corp has filed an SEC filing for an offering of four-part Euro-denominated senior notes. The size of this offering has not been disclosed. This news comes from Reuters via TradingView.

Andrew Slimmon, Senior Portfolio Manager at Morgan Stanley Investment Management, suggests that geopolitical events often present favorable buying opportunities in the market. He elaborated on this perspective during an appearance on 'Squawk Box,' where he also discussed current market trends, the implications of the Iran war, and his outlook on oil prices.

Northrop Grumman reported strong Q1 FY26 earnings and sales, exceeding analyst estimates, driven by modernization efforts and high demand in the defense sector. The company reiterated its FY26 guidance and highlighted a potential increase in defense spending to Cold War-era levels if the proposed $1.5 trillion FY27 defense budget is implemented. This budget prioritizes modernization with a significant increase over current spending, supporting major programs like B-21 and Sentinel.

OVERSEA CHINESE BANKING Corp Ltd reduced its stake in Welltower Inc. (NYSE:WELL) by 13.5% in the fourth quarter, selling 16,441 shares and holding 104,967 shares valued at $19.48 million. Other institutional investors also adjusted their positions in the healthcare REIT. Welltower recently reported strong quarterly earnings, beating analyst estimates, and declared a quarterly dividend of $0.74 per share.

OVERSEA CHINESE BANKING Corp Ltd decreased its holdings in Arista Networks, Inc. by 8.9% in the fourth quarter, selling 5,951 shares and retaining 60,620 shares valued at $7.96 million. Despite this reduction, many other institutional investors and hedge funds increased their stakes in ANET, with total institutional ownership standing at 82.47%. The article also notes mixed sentiment regarding Arista Networks, with positive analyst outlooks due to AI data-center spending and strong earnings, balanced against significant insider share sales.

Philip Morris International (PMI) announced its 2026 first-quarter results, exceeding expectations with a 16.0% adjusted diluted EPS growth, driven by strong IQOS performance. Net revenues increased 9.1% to $10.1 billion, with smoke-free products accounting for 43% of total net revenues. The company updated its 2026 full-year adjusted diluted EPS forecast based on currency impacts, projecting an increase of 7.5% to 9.5% excluding currency.

Migdal Insurance & Financial Holdings Ltd. has acquired a new stake of 475,000 shares in Uber Technologies, Inc., valued at approximately $38.8 million, increasing institutional ownership to 80.24%. Uber's strategic moves include a significant stake and expanded robo-taxi fleet arrangements with Lucid, signaling a strong commitment to autonomous vehicles. Despite missing recent EPS estimates, Uber's revenue increased by 20.1% year-over-year, and analysts maintain a "Moderate Buy" consensus with an average target price of $105.14.

KeyCorp (NYSE: KEY) is acquiring Clearwater Corporate Finance LLP (Clearwater UK), a move that will expand Key's middle-market M&A advisory capabilities into Western Europe. This acquisition builds on a 2020 collaboration and aims to connect US clients with European acquisition targets and provide European clients access to the US M&A market. The deal is expected to close in the second half of 2026, pending UK regulatory approval.

Labcorp has made Agilent Technologies' PD-L1 IHC 22C3 pharmDx, an FDA-approved companion diagnostic, available nationwide. This diagnostic identifies patients with platinum-resistant ovarian cancer who are eligible for treatment with Merck's KEYTRUDA® or KEYTRUDA QLEX™. The initiative aims to provide critical access to new treatment options for patients with this challenging form of cancer, following rapid readiness activities by Labcorp.

Labcorp has announced the nationwide availability of Agilent's FDA-approved PD-L1 IHC 22C3 pharmDx, a companion diagnostic for identifying platinum-resistant ovarian cancer patients eligible for Merck's KEYTRUDA therapies. This diagnostic helps clinicians identify patients who may benefit from these new treatment options because approximately 80% of ovarian cancer patients experience recurrence and resistance to platinum-based chemotherapy. Labcorp's participation in Agilent's Early Validation Program ensured a rapid rollout of this critical diagnostic test.